Cidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis At Upcoming IDSOG Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical studies evaluating its novel Phase 2 echinocandin CD101 as a topical treatment for vulvovaginal candidiasis (VVC) will be presented at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) in Annapolis, Maryland from August 11-13, 2016. Results from a national survey of 478 U.S. women with VVC will also be presented.

Back to news